Advertisement

International Journal of Hematology

, Volume 100, Issue 2, pp 171–179 | Cite as

Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol

  • Hideki NakayamaEmail author
  • Ken Tabuchi
  • Akio Tawa
  • Ichiro Tsukimoto
  • Masahiro Tsuchida
  • Akira Morimoto
  • Hiromasa Yabe
  • Keizo Horibe
  • Ryoji Hanada
  • Masue Imaizumi
  • Yasuhide Hayashi
  • Kazuko Hamamoto
  • Ryoji Kobayashi
  • Kazuko Kudo
  • Akira Shimada
  • Takako Miyamura
  • Hiroshi Moritake
  • Daisuke Tomizawa
  • Takashi Taga
  • Souichi Adachi
Original Article

Abstract

The outcomes of children with relapsed acute myeloid leukemia (AML) are known to be poor, but remain obscure. We retrospectively analyzed 71 patients who had relapsed following first-line treatment under the AML99 protocol. We investigated the time and site of recurrence, response to re-induction therapy, and performance of hematopoietic stem cell transplantation (HSCT) in relapsed cases, and performed a multivariate analysis to identify prognostic factors. The 5-year overall-survival (OS) rate after relapse was 37 %. Of 71 patients, three died without any anti-leukemic therapy and two underwent allogeneic HSCT. The remaining 66 patients received re-induction chemotherapy, and 33 (50 %) achieved second CR (CR2). Twenty-two of 25 (88 %) late relapse patients and 11 of 41 (27 %) early relapse patients achieved CR2 (P < 0.001). Twenty-nine CR2 cases and 35 non-CR2 cases underwent allogeneic HSCT. The 5-year OS rate was significantly higher in patients who underwent HSCT in CR2 than those in non-CR2 (66 vs. 17 %, P < 0.000001). Multivariate analysis indicated that early relapse (P < 0.05) and the positivity of the FMS-like tyrosine kinase 3—internal tandem duplication (P < 0.05) were adverse prognostic factors for survival. In conclusion, the etiology of relapsed pediatric AML needs to be elucidated and effective chemotherapy should be administered to obtain CR2.

Keywords

Acute myeloid leukemia (AML) Relapse Children Hematopoietic stem cell transplantation (HSCT) Second complete remission (CR2) 

Notes

Acknowledgments

The authors deeply appreciate the invaluable cooperation by the large number of physicians working at institutions affiliated to The Japanese Childhood AML Cooperative Study Group and The Japanese Pediatric Leukemia/Lymphoma Study Group. Research was supported by Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare of Japan.

Conflict of interest

The authors declare no conflict of financial interest.

References

  1. 1.
    Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, et al. Outcome in 146 patients with pediatric acute myeloid leukemia treated according to the AML99 protocol in the period 2003–06 from the Japan Association of Childhood Leukemia Study. Br J Haematol. 2012;159:204–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Webb DKH, Wheatley K, Harrison G, Stevens RF, Hann IM, et al. Outcome for children with relapsed acute myeloid leukemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia. 1999;13:25–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Aladjidi N, Auvrigno A, Leblanc T, Perel Y, Berard A, Bordigoni P, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol. 2003;21:4377–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: children’s Cancer Group Study 2951. J Clin Oncol. 2003;21(15):2940–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B, et al. Improved outcome after relapse in children with acute myeloid leukemia. Br J Haematol. 2007;136(2):229–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trails. Leukemia. 2010;24:1422–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a therapeutic advances in childhood leukemia (TACL) consortium study. Pediatric Blood Cancer. 2010;55(3):421–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaspers GJL, Zimmermann M, Reinhardt D, Gibson BES, Tamminga RYJ, Aleinikova O, et al. Improved outcome in pediatric acute myeloid leukemia: results of randomized trial on Liposomal Daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599–607.PubMedCrossRefGoogle Scholar
  10. 10.
    Kanda Y. Investigation of the freely available easy-to-use software “EZR” (Easy R) for medical statics. Bone Marrow Transplant. 2013;48:452–8.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103:1085–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;31:187–90.Google Scholar
  13. 13.
    Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107:1806–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Shimada A, Taki T, Tabuchi K, Taketani T, Hanada R, Tawa A, et al. Tandem duplication of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML cooperative Study Group. Pediatr Blood Cancer. 2008;50(2):264–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Jamal R, Taketani T, Taki T, et al. Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2001;31:187–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Schnittger S, Wormann B, Hiddemann W, et al. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood. 1998;92:1728–34.PubMedGoogle Scholar
  17. 17.
    Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, et al. Low frequency of KIT mutations in pediatric acute myeloid leukemia with inv(16)(p13q22): a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2007;86:289–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Sano H, Shimada A, Tabuchi K, Taki T, Murata C, Park MJ, et al. WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2013;98:437–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674–81.PubMedCrossRefGoogle Scholar
  20. 20.
    Von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682–9.CrossRefGoogle Scholar
  21. 21.
    Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from international expert panel. Blood. 2012;120(16):3187–205.PubMedCrossRefGoogle Scholar
  22. 22.
    Fleischhack G, Hassan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998;102(3):647–55.PubMedCrossRefGoogle Scholar
  23. 23.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr. 2000;42(3):198–204.PubMedGoogle Scholar
  24. 24.
    Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:2390–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148(5):768–76.PubMedCrossRefGoogle Scholar
  26. 26.
    Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009;27(26):4392–7.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukemia. Br J Haematol. 2011;155(2):182–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Miano M, Pistorio A, Putti MC, Dufour C, Messina C, Barisone E, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma. 2012;53(9):1693–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Davila J, Slotkin E, Renaud T. Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments. Pediatr Drugs. 2014;16:151–68.CrossRefGoogle Scholar
  30. 30.
    Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of Flt3 and N-ras gene mutations in acute myeloid leukemia. Blood. 1999;93:3074–80.PubMedGoogle Scholar
  31. 31.
    Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89–94.PubMedCrossRefGoogle Scholar
  33. 33.
    Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003;102:2387–94.PubMedCrossRefGoogle Scholar
  34. 34.
    Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, et al. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2012;96(4):469–76.PubMedCrossRefGoogle Scholar
  35. 35.
    Fagioli F, Zecca M, Locatelli F, Lanino E, Uderzo C, Di Bartolomeo P, et al. Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. J Pediatr Hematol Oncol. 2008;30:575–83.PubMedCrossRefGoogle Scholar
  36. 36.
    Isoyama K, Oda M, Kato K, Nagamura-Inoue T, Kai S, Kigasawa H, et al. Long-term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan. Bone Marrow Transplant. 2010;45:69–77.PubMedCrossRefGoogle Scholar
  37. 37.
    The Japan Society for Hematopoietic Cell Transplantation Annual Report of Nationwide Survey 2012, JSHCT monograph, vol. 38, p. 97–127 (in Japanese), ISSN 1344-5898.Google Scholar
  38. 38.
    Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer. 2007;109:157–63.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2014

Authors and Affiliations

  • Hideki Nakayama
    • 1
    Email author
  • Ken Tabuchi
    • 2
  • Akio Tawa
    • 3
  • Ichiro Tsukimoto
    • 4
  • Masahiro Tsuchida
    • 5
  • Akira Morimoto
    • 6
  • Hiromasa Yabe
    • 7
  • Keizo Horibe
    • 8
  • Ryoji Hanada
    • 9
  • Masue Imaizumi
    • 10
  • Yasuhide Hayashi
    • 11
  • Kazuko Hamamoto
    • 12
  • Ryoji Kobayashi
    • 13
  • Kazuko Kudo
    • 14
  • Akira Shimada
    • 15
  • Takako Miyamura
    • 16
  • Hiroshi Moritake
    • 17
  • Daisuke Tomizawa
    • 18
  • Takashi Taga
    • 19
  • Souichi Adachi
    • 20
  1. 1.Department of Pediatrics, National Hospital OrganizationFukuoka-Higashi Medical CenterKogaJapan
  2. 2.Department of PediatricsTokyo Metropolitan Komagome HospitalTokyoJapan
  3. 3.Department of Pediatrics, National Hospital OrganizationOsaka Medical CenterOsakaJapan
  4. 4.Saiseikai Kanagawa Eastern HospitalYokohamaJapan
  5. 5.Ibaraki Children’s HospitalMitoJapan
  6. 6.Department of PediatricsJichi Medical SchoolShimonoJapan
  7. 7.Department of PediatricsTokai University School of MedicineIseharaJapan
  8. 8.Clinical Research Department, National Hospital OrganizationNagoya Medical CenterNagoyaJapan
  9. 9.Department of Hematology/OncologySaitama Children’s Medical CenterSaitamaJapan
  10. 10.Department of Hematology and OncologyMiyagi Children’s HospitalSendaiJapan
  11. 11.Gunma Children’s Medical CenterMaebashiJapan
  12. 12.Department of PediatricsHiroshima Red Cross and Atomic Bomb Survivors HospitalHiroshimaJapan
  13. 13.Department of PediatricsHokuyuh HospitalSapporoJapan
  14. 14.Department of Hematology/OncologyShizuoka Children’s HospitalShizuokaJapan
  15. 15.Department of PediatricsOkayama University School of MedicineOkayamaJapan
  16. 16.Department of PediatricsOsaka University School of MedicineOsakaJapan
  17. 17.Division of Pediatrics, Department of Reproductive and Developmental Medicine, Faculty of MedicineUniversity of MiyazakiMiyazakiJapan
  18. 18.Department of PediatricsTokyo Medical and Dental UniversityTokyoJapan
  19. 19.Department of PediatricsShiga University of Medical ScienceShigaJapan
  20. 20.Human Health SciencesKyoto UniversityKyotoJapan

Personalised recommendations